US FDA Panel Weighs Easing Restrictions on Peptide Compounding

A U.S. Food and Drug Administration advisory panel is considering whether seven popular peptide drugs can be compounded by licensed pharmacies ^[1].

The decision could expand patient access to these therapies, but it pits political pressure for accessibility against the warnings of federal scientists regarding safety and efficacy.

The Pharmacy Compounding Advisory Committee (PCAC) held a two-day meeting in Washington, D.C., during the first week of July [2, 3]. The panel is reviewing the status of seven specific peptide drugs to determine if current restrictions on their compounding should be eased ^[1].

FDA staff expressed concerns prior to the meeting and said there is little evidence to support the benefits of these peptides ^[3]. In a briefing reported on June 30, agency scientists warned of potential safety risks associated with the expanded use of these substances ^[3].

Despite these warnings, the panel's composition has drawn scrutiny. Reports indicate that at least seven members of the PCAC have ties to peptide businesses ^[4]. This overlap has fueled debate over whether the panel's recommendations will prioritize industry growth and patient access over the cautious approach advocated by FDA staff.

Peptide therapies have seen a surge in popularity, leading to increased demand for compounded versions, which are often cheaper or more readily available than brand-name pharmaceuticals. The PCAC is tasked with weighing this demand against the regulatory requirement to ensure drug safety, and quality.